Loading…
Monopar Therapeutics Inc. is projected to rise to $136.97 by 2027, a +28% move from its current price of $106.60. MNPR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $102.73 | $106.71 | $110.84 | +0.10% |
| Jul 14 | $101.23 | $106.81 | $112.70 | +0.20% |
| Jul 15 | $100.12 | $106.92 | $114.19 | +0.30% |
| Jul 16 | $99.20 | $107.03 | $115.47 | +0.40% |
| Jul 17 | $98.42 | $107.14 | $116.63 | +0.50% |
| Jul 18 | $97.72 | $107.24 | $117.69 | +0.60% |
| Jul 19 | $97.09 | $107.35 | $118.69 | +0.71% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $97.09 | $107.35 | $118.69 | +0.71% |
| Week 2 | $93.79 | $108.11 | $124.61 | +1.42% |
| Week 3 | $91.49 | $108.87 | $129.56 | +2.13% |
| Week 4 | $89.69 | $109.64 | $134.03 | +2.85% |
| Week 5 | $88.20 | $110.41 | $138.21 | +3.58% |
| Week 6 | $86.94 | $111.19 | $142.20 | +4.31% |
| Week 7 | $85.85 | $111.97 | $146.05 | +5.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops therapeutics for the treatment of cancer in the United States. The company is focused on advancing late-stage, investigational medicines, including ALXN1840 as a daily oral treatment, MNPR-101 as a proprietary monoclonal antibody conjugated with radioisotopes for solid tumors expressing urokinase plasminogen activator receptor, MNPR-101-Zr as a radiopharmaceutical imaging agent, and MNPR-101-Lu as a radiotherapeutic in Phase 1a.
Monopar was founded in 2014 and is headquartered in Wilmette, Illinois.
The company has collaborations with NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19, Excel Diagnostics and Nuclear Oncology Center for MNPR-101-Zr and MNPR-101-Lu, and a license agreement with Alexion to develop and commercialize ALXN1840 for Wilson disease.
Monopar Therapeutics Inc. (MNPR) trades with a current price of $106.60 and a market capitalization of $714.12M, ranking 2772 by market cap.
The stock is positioned within the healthcare sector as a clinical-stage oncology-focused biopharmaceutical company with multiple programs in development. The price outlook shows a multi-year rise in the modeled averages, beginning at a 2026 average price of $106.60 and expanding significantly through 2050 to a forecast average of $2,094.07, with bullish sentiment prevailing in later years.
A major floor 59.4% below — a decisive break under it would weaken the trend.
The nearest floor, 44.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 29.7% above — clearing it would confirm fresh momentum.
Key MNPR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MNPR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $100.54 | Buy | $101.53 | Buy |
| MA 10 | $97.04 | Buy | $96.26 | Buy |
| MA 20 | $83.60 | Buy | $87.45 | Buy |
| MA 50 | $69.64 | Buy | $74.77 | Buy |
| MA 100 | $62.77 | Buy | $68.51 | Buy |
| MA 200 | $69.50 | Buy | $63.28 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 83.39 | Sell |
| Stoch RSI (14) | 89.99 | Sell |
| CCI (20) | 106.63 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 1.74 | Buy |
| ROC (12) | 30.37 | Buy |
| Bollinger %B (20,2) | 0.86 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 1.85 | Buy |
| Awesome (5,34) | 25.83 | Buy |
| Ultimate (7,14,28) | 86.27 | Sell |
| Momentum (10) | 18.97 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 104.09 | Buy |
| ADX (14) | 44.57 | Buy |
| ATR (14) | 2.71 | Info |
The 30-day technical picture is bullish, supported by a bullish overall sentiment and momentum indicators. RSI14 is at 80, while the stock trades above notable moving averages, with SMA50 at $69.64 and SMA200 at $69.50.
Support is positioned at $59.10 and resistance at $106.60. Over the past 30 days, the price ranged from $83.00 to $136.91, indicating a broad trading band. The annualized volatility is 70%, reflecting notable price fluctuations within the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $50.12 | $106.60 | $153.90 | 0% | Neutral | |
| $105.10 | $136.97 | $191.04 | +28% | Bullish | |
| $150.01 | $203.58 | $298.09 | +91% | Bullish | |
| $196.76 | $276.24 | $420.04 | +159% | Bullish | |
| $191.20 | $276.70 | $434.19 | +160% | Bullish | |
| $215.45 | $320.60 | $516.98 | +201% | Bullish | |
| $242.45 | $370.36 | $611.91 | +247% | Bullish | |
| $241.89 | $378.77 | $639.69 | +255% | Bullish | |
| $332.88 | $533.77 | $919.75 | +401% | Bullish | |
| $391.85 | $642.88 | $1,128.51 | +503% | Bullish | |
| $590.51 | $1,077.57 | $2,043.07 | +911% | Bullish | |
| $946.73 | $2,097.77 | $4,441.01 | +18.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $50.12 | $106.60 | $133.91 | +0.00% |
| August 2026 | $99.06 | $118.15 | $145.57 | +10.83% |
| September 2026 | $96.98 | $116.82 | $146.13 | -1.13% |
| October 2026 | $94.20 | $114.44 | $144.99 | -2.04% |
| November 2026 | $96.61 | $118.21 | $151.36 | +3.29% |
| December 2026 | $96.62 | $119.02 | $153.90 | +0.69% |
Click any year to see its month-by-month MNPR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, MNPR could reach as high as $153.90, with a base case around $106.60 and support toward $50.12 — roughly 0% from $106.60. Price action looks broadly range-bound.
Expect MNPR to range from $105.10 to $191.04 through 2027. The $136.97 average target implies a +28% move from current prices. That is up +28% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The MNPR price prediction for 2028 points to an average of $203.58 (low $150.01, high $298.09) — a potential gain of +91% on today's $106.60. Momentum favours further upside here.
In 2029, MNPR is projected to trade between $196.76 and $420.04, averaging $276.24 — a potential gain of +159% from today's $106.60. That is up +36% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Monopar Therapeutics Inc.'s 2030 outlook centres on $276.70, within a $191.20 to $434.19 range. That is up 0% on the projected 2029 average. That marks a +160% change versus current levels. Momentum favours further upside here.
By 2031, MNPR could reach as high as $516.98, with a base case around $320.60 and support toward $215.45 — roughly +201% from $106.60. Buyers look set to stay in control over this stretch.
Expect MNPR to range from $242.45 to $611.91 through 2032. The $370.36 average target implies a +247% move from current prices. That is up +16% on the projected 2031 average. Momentum favours further upside here.
The MNPR price prediction for 2033 points to an average of $378.77 (low $241.89, high $639.69) — a potential gain of +255% on today's $106.60. Buyers look set to stay in control over this stretch.
In 2034, MNPR is projected to trade between $332.88 and $919.75, averaging $533.77 — a potential gain of +401% from today's $106.60. That is up +41% on the projected 2033 average. Momentum favours further upside here.
Monopar Therapeutics Inc.'s 2035 outlook centres on $642.88, within a $391.85 to $1,128.51 range. That is up +20% on the projected 2034 average. That marks a +503% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, MNPR could reach as high as $2,043.07, with a base case around $1,077.57 and support toward $590.51 — roughly +911% from $106.60. Momentum favours further upside here.
Expect MNPR to range from $946.73 to $4,441.01 through 2050. The $2,097.77 average target implies a +18.7x move from current prices. That is up +95% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in MNPR today (≈ 9.380863 MNPR) could be worth
$19,678.87
+$18,678.87 (+1868%) by 2050 · US Dollar
Based on the average projected MNPR price of $2,097.77 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MNPRwould be worth at today's price.
$1,000 invested in MNPR on Jul 10, 2025 (≈ 26.136959 MNPR) would be worth
$2,786.2
+$1,786.2 (+178.6%) today · 2.79× · US Dollar
Based on a MNPR entry price of $38.26 vs. today's $106.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $97.79 | $1,090.09 | +9.0% |
| 1 month ago | $59.42 | $1,794.01 | +79.4% |
| 3 months ago | $56.08 | $1,900.86 | +90.1% |
| 6 months ago | $65.03 | $1,639.24 | +63.9% |
| 1 year ago | $38.26 | $2,786.2 | +178.6% |
| All time (5.0y) ago | $28.05 | $3,800.36 | +280.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MNPR forecast.
Our base-case forecast reaches $210.00 around 2029.
Implied market cap at $210.00: $1.41B
The long-term forecast shows a rising trajectory through 2035 and beyond. In 2026 the average price is projected at $106.60 with a min of $50.12 and a max of $153.79 and ROI of 0%, with neutral sentiment.
From 2027 onward, the outlook strengthens: 2027 avg $137.11 (min $105.20, max $191.27; ROI 28.6%; bullish); 2028 avg $204.03 (min $150.33, max $298.80; ROI 91.4%; bullish); 2029 avg $276.07 (min $196.61, max $419.81; ROI 159%; bullish); 2030 avg $276.63 (min $191.14, max $434.11; ROI 159.5%; bullish).
Continuing into the 2030s, the forecast shows further gains: 2031 avg $321.14 (min $215.80, max $517.89; ROI 201.3%; bullish); 2032 avg $370.27 (min $242.38, max $611.82; ROI 247.3%; bullish); 2033 avg $378.62 (min $241.78, max $639.47; ROI 255.2%; bullish); 2034 avg $534.64 (min $333.40, max $921.29; ROI 401.5%; bullish); 2035 avg $642.97 (min $391.87, max $1,128.71; ROI 503.2%; bullish).
Looking further ahead, 2040 shows avg $1,080.13 (min $591.88, max $2,048.01; ROI 913.3%; bullish) and 2050 shows avg $2,094.07 (min $945.02, max $4,433.30; ROI 1864.4%; bullish). These figures are estimates and not guarantees, and actual results may vary.
Tap a question to reveal the answer.
2030 average price is projected to be $276.63 with a minimum of $191.14 and a maximum of $434.11; ROI is 159.5% and sentiment is bullish.
Forecasts indicate bullish sentiment from 2027 onward with rising average prices (e.g., $137.11 in 2027, $204.03 in 2028, $276.07 in 2029, and $276.63 in 2030) and meaningful ROIs (up to 159.5% in 2030 and higher in later years). However, these are estimates and not guarantees.
Yes, the forecast shows an average price of $2,094.07 in 2050, with a 2050 max of $4,433.30 and a 2050 min of $945.02; the 2040 average is $1,080.13, with a max of $2,048.01.
$714.12M.
Monopar Therapeutics Inc. Community Discussion
0Share your Monopar Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.